Sarcoidosis vs Idiopathic Pulmonary Fibrosis: How to Tell Them Apart
Both sarcoidosis and IPF cause a restrictive pattern with reduced DLCO and are diagnosed with HRCT as the cornerstone. The core axis that separates them: sarcoidosis is a multisystem, non-caseating granulomatous disease that often remits or responds to steroids, whereas IPF is a chronic, progressive fibrosing pneumonia limited to the lungs with the UIP pattern and a poor prognosis. Getting this distinction right is critical because immunosuppression helps sarcoidosis but is harmful in IPF.
How to tell them apart
| Feature | Sarcoidosis | Idiopathic pulmonary fibrosis |
|---|---|---|
| Systemic involvement | Multisystem granulomatous disease that can affect virtually any organ (eyes, skin, heart, nervous system, liver/spleen, joints); lungs and thoracic nodes involved in >90% | Limited to the lungs with no systemic involvement |
| Typical age | Peak age 25–40 years | Older adults, usually >60 years |
| Demographics | Higher incidence in African Americans (more severe disease) and Scandinavians; women slightly more than men | Primarily older adults |
| HRCT / chest imaging | Bilateral hilar adenopathy (staging on CXR); upper lobe nodules | UIP pattern: basal and peripheral predominant distribution, honeycombing, reticulation, and traction bronchiectasis |
| Histopathology | Non-caseating granulomas with negative stains/cultures for infection | Usual Interstitial Pneumonia (UIP): spatial and temporal heterogeneity with fibroblastic foci adjacent to established collagen, subpleural/paraseptal honeycombing |
| Characteristic exam findings | Erythema nodosum, lupus pernio, uveitis, facial nerve palsy | Fine, "Velcro-like" crackles at the lung bases; clubbing |
| Laboratory findings | ACE elevated in ~60% (nonspecific); hypercalcemia and hypercalciuria from granuloma 1-alpha-hydroxylase | No specific diagnostic laboratory marker |
| Prognosis | Often favorable; Stage I disease has >80% spontaneous remission; Löfgren syndrome usually resolves spontaneously | Worst prognosis among idiopathic interstitial pneumonias; median survival 3–5 years from diagnosis |
| Treatment | Corticosteroids when indicated (symptomatic/progressive pulmonary disease, significant extrapulmonary involvement, hypercalcemia); observation for asymptomatic Stage I | Antifibrotics; immunosuppression is harmful |
The reasoning
Anchor on the two axes: age/systemic pattern and HRCT. A younger patient (25–40) with bilateral hilar adenopathy, extrapulmonary findings (erythema nodosum, uveitis, facial nerve palsy, hypercalcemia), and non-caseating granulomas points to sarcoidosis. An older patient (>60) with basal, peripheral honeycombing on HRCT (definite UIP), Velcro crackles, clubbing, and disease confined to the lungs points to IPF. When HRCT shows a confident UIP pattern, biopsy is often unnecessary to diagnose IPF. Sarcoidosis is a diagnosis of exclusion—rule out infection (especially TB and fungal), malignancy/lymphoma causing hilar adenopathy, and berylliosis before committing. The therapeutic stakes arbitrate errors: steroids/immunosuppression treat sarcoidosis but are harmful in IPF, where antifibrotics are indicated.
Key tests
- HRCT: sarcoidosis shows bilateral hilar adenopathy and upper lobe nodules, while IPF shows a UIP pattern with basal/peripheral honeycombing, reticulation, and traction bronchiectasis
- Tissue biopsy: sarcoidosis shows non-caseating granulomas (with negative infectious stains/cultures); IPF shows the UIP pattern with fibroblastic foci and temporal heterogeneity
- Laboratory testing: elevated ACE (in ~60%, nonspecific), hypercalcemia, and hypercalciuria support sarcoidosis; IPF has no specific serologic marker
- PFTs with DLCO: both can show restriction with reduced DLCO, but sarcoidosis PFTs may be normal, obstructive, restrictive, or mixed
What they share
- Both are interstitial lung diseases that can produce a restrictive pattern on PFTs (reduced TLC and FVC with normal or elevated FEV1/FVC)
- Both can show reduced DLCO, reflecting loss of alveolar-capillary surface area
- HRCT is the cornerstone of diagnosis for both
- Both present with progressive dyspnea and cough
- Tissue biopsy can be used to establish the diagnosis in both when non-invasive workup is inconclusive
Pitfalls
- Sarcoidosis is a diagnosis of exclusion—failing to rule out infection (TB, fungal), lymphoma, and berylliosis before diagnosing it is a classic trap
- Berylliosis is clinically, radiologically, and histologically nearly indistinguishable from sarcoidosis; take a detailed occupational history and use the beryllium lymphocyte proliferation test (BeLPT) when exposure is possible
- Giving immunosuppression for a presumed inflammatory ILD when the patient actually has IPF is harmful—confirm the UIP pattern and the absence of systemic disease
- A normal or elevated ACE level does not confirm or exclude sarcoidosis; it is nonspecific and only elevated in about 60%
- Fibrotic/chronic hypersensitivity pneumonitis can mimic the UIP/honeycombing pattern of IPF and granulomas of sarcoidosis—always ask about birds, molds, and hot tubs to avoid mislabeling
Practice this the way the exam tests it — on branching cases where your decisions shape the patient.